Pegylated liposomal doxorubicin (PLD) treatment for recurrent epithelial ovarian cancer (rEOC): Implications of BRCA mutations

被引：1
|
作者：
Safra, T.
Borgato, L.
Nicoletto, M.
Rolnitzky, L.
Curtin, J.
Geva, R.
Peles, S.
Grenader, T.
Gabizon, A.
Muggia, F.
机构：
[1] Tel Aviv Med Ctr & Sch Med, Tel Aviv, Israel
[2] IOV, Padua, Italy
[3] NYU Med Ctr, New York, NY 10016 USA
[4] SZMC, Jerusalem, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.5043
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5043
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A RANDOMIZED PHASE III STUDY OF TRABECTEDIN WITH PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) VERSUS PLD IN RELAPSED, RECURRENT OVARIAN CANCER (OC)
    Monk, B. J.
    Herzog, T.
    Kaye, S.
    Krasner, C. N.
    Vermorken, J.
    Muggia, F.
    Pujade-Lourraine, E.
    Renshaw, F. G.
    Lebedinsky, C.
    Poveda, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 2 - 2
  • [22] Efficacy and safety of generic pegylated liposomal doxorubicin (PLD) in relapsed ovarian cancer
    Ghosh, I.
    Dwary, A.
    Dabkara, D.
    Bhaumik, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S731 - S731
  • [23] A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer
    Adams, Sarah F.
    Marsh, Evelyn B.
    Elmasri, Wafic
    Halberstadt, Steffanie
    VanDecker, Stephanie
    Sammel, Mary D.
    Bradbury, Angela R.
    Daly, Mary
    Karlan, Beth
    Rubin, Stephen C.
    GYNECOLOGIC ONCOLOGY, 2011, 123 (03) : 486 - 491
  • [24] CA-125 Response Patterns in Patients With Recurrent Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (PLD)
    Oaknin, Ana
    Barretina, Pilar
    Perez, Xavier
    Jimenez, Laura
    Velasco, Montserrat
    Alsina, Maria
    Brunet, Joan
    Ramon Germa, Josep
    Beltran, Miguel
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (01) : 87 - 91
  • [25] Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer
    Faruk Tas
    Duygu Derin
    Nese Guney
    Adnan Aydiner
    Erkan Topuz
    International Journal of Clinical Oncology, 2008, 13 : 330 - 334
  • [26] Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer
    Tas, Faruk
    Derin, Duygu
    Guney, Nese
    Aydiner, Adnan
    Topuz, Erkan
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2008, 13 (04) : 330 - 334
  • [27] Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer
    Chambers, Laura M.
    Pendlebury, Adam
    Rose, Peter G.
    Yao, Meng
    DeBernardo, Robert
    GYNECOLOGIC ONCOLOGY, 2020, 158 (02) : 309 - 315
  • [28] Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®):: Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer
    Andreopoulou, E.
    Gaiotti, D.
    Kim, E.
    Downey, A.
    Mirchandani, D.
    Hamilton, A.
    Jacobs, Allan
    Curtin, John
    Muggia, F.
    ANNALS OF ONCOLOGY, 2007, 18 (04) : 716 - 721
  • [29] Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer
    Monk, B. J.
    Herzog, T. J.
    Kaye, S. B.
    Krasner, C. N.
    Vermorken, J. B.
    Muggia, F.
    Pujade-Lourraine, E.
    Zintl, P.
    Parekh, T. V.
    Poveda, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] Recurrent ovarian cancer: Treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience
    Dear, Rachel F.
    Gao, Bo
    Harnett, Paul
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2010, 6 (01) : 66 - 73
12345